The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ORGANIZATION
ORGANIZATION
- US, European Lobbies Set Out Healthcare Policy Proposals for Japan
June 1, 2015
- JPWA Chief Suzuki Renews His Resolve as He Wins Second Term
June 1, 2015
- JPMA Extends Suspension of Activities for Takeda as It Awaits Ruling of Administrative Authority on Blopress Scandal
May 29, 2015
- Doctors Need to Be More Cost-Conscious When Prescribing: Dr Imamura of JMA
May 29, 2015
- FPMAJ, JPMA, and JGA Call for “Balanced” Approach to Control Drug Expenditure in Joint Declaration
May 28, 2015
- Generic Makers Need More Time to Meet Higher Target: JGA Leader
May 27, 2015
- 3 Companies Received Guidance, 2 Received Warnings in FY2014 due to Fair Competition Code Violations: Maker’s FTC
May 27, 2015
- JPMA Chief Fires at Proposed 80-90% Generic Share Target
May 27, 2015
- JPMA Official Praises Sakigake System as “Ground-Breaking,” Expresses Concern Over Impact of Compassionate Use System
May 12, 2015
- “Stable Supply System” Key for Adopting Generics at Insurance Pharmacies: JGA Survey
May 11, 2015
- JPMA Preparing “Action Guidelines” to Ensure Greater Transparency
April 24, 2015
- Expert Warns against Research-Driven Makers’ Foray into Indian Market
April 22, 2015
- JPMA to Step Up Calls for Biowaivers Using IVIVC
April 21, 2015
- MHLW to Inquire with Drug Makers about Payments to PAFSC Members
April 17, 2015
- Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
- APAC Approves “Good Submission Practice” Guidelines Aimed at Reducing Time to Approval in Asia
April 13, 2015
- JPA Vice President Disagrees with Exclusion of OTC-Like Drugs from Insurance Coverage
April 13, 2015
- JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
- October-December Generic Share Down 1.3 Points from Prior Qtr: JGA
March 27, 2015
- 15 Drug Makers to Jointly Purchase 150,000 Compounds for Compound Libraries Over 5-Year Period Starting in FY2015
March 27, 2015
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…